PFE SEC Filings: 8-K, 10-Q, S-3 & 424B – Pfizer

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 3, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

11-K

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Jun 16, 2026

11-K

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Jun 16, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

News

TYPE

HEADLINE

FILED AT

8-K

Pfizer Appoints Cecile Guegan as Chief Financial Officer and Executive Vice President

Nov 3, 2026

8-K

Pfizer Inc. Reports Third Quarter 2026 Financial Results

Nov 3, 2026

8-K

Pfizer Inc. Reports Second Quarter 2026 Financial Results

Aug 4, 2026

8-K

Pfizer Reaffirms Full-Year 2026 Financial Guidance

Jun 18, 2026

8-K

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026

8-K

Pfizer Inc. Reports First Quarter 2026 Financial Results

May 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

FIXED PRICE OFFERING - NOTES | Offering amount: $5,990,635,000 | Bank: Citigroup, Deutsche Bank Securities, J.P. Morgan, Mizuho, Barclays, HSBC, UBS Investment Bank

Nov 20, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Nov 18, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 15, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

May 13, 2025

424B5

Common Stock

May 18, 2023

424B3

Common Stock

May 15, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 5, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Nov 18, 2025

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

May 19, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

May 14, 2025

POSASR

Form POSASR - Post-effective Amendment to an automatic shelf registration statement

May 13, 2025

SC TO-I/A

with respect to Common Stock, Par Value $0.05 Per Share

Sep 13, 2024

Proxies

TYPE

HEADLINE

FILED AT

N-PX

Form N-PX - Annual Report of proxy voting record of management investment companies

Aug 31, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 12, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 12, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 11, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

Form SD - Specialized disclosure report

May 30, 2025

CORRESP

Form CORRESP - Correspondence

Aug 22, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 15, 2024

Form SD - Specialized disclosure report

May 31, 2024

LETTER

Form UPLOAD - SEC-generated letter

Apr 14, 2022

CORRESP

Form CORRESP - Correspondence

Apr 12, 2022

Pfizer Inc. PFE · SEC Filings